Today: 30 June 2026
Browse Category

Stock Market 17 January 2026

Microsoft stock price: MSFT faces Musk’s $134 billion claim ahead of Jan. 28 earnings

Microsoft stock price: MSFT faces Musk’s $134 billion claim ahead of Jan. 28 earnings

New York, Jan 17, 2026, 09:35 EST — Market closed. Microsoft shares are heading into next week with a new legal cloud looming. Elon Musk claims he’s after as much as $134 billion from OpenAI and Microsoft over what he calls “wrongful gains.” Musk told a federal court that OpenAI made between $65.5 billion and $109.4 billion, while Microsoft pulled in $13.3 billion to $25.1 billion from his early backing. The case is set for a jury trial in April. Friday’s session saw MSFT gain 0.7%, closing at $459.86, though it’s still down roughly 3.6% on the week.
17 January 2026
····
Google stock (GOOG) heads into a long weekend after fresh antitrust filing — what to watch next

Google stock (GOOG) heads into a long weekend after fresh antitrust filing — what to watch next

New York, Jan 17, 2026, 09:35 EST — Market closed. On Friday, Google requested a U.S. judge to halt a data-sharing order tied to its search antitrust case, arguing against handing over data to rivals — including generative AI companies like OpenAI, the creator of ChatGPT — during its appeal, court documents revealed. Alphabet’s Class C shares dropped $2.79, or roughly 0.8%, closing at $330.34.
17 January 2026
··
Micron’s $1.8B Taiwan fab plan puts MU in focus after Friday’s 7.8% pop

Micron’s $1.8B Taiwan fab plan puts MU in focus after Friday’s 7.8% pop

New York, Jan 17, 2026, 08:34 EST — Market closed Micron Technology announced Saturday it has entered into an exclusive letter of intent to buy Powerchip Semiconductor Manufacturing Corp’s P5 fabrication facility in Tongluo, Taiwan, for $1.8 billion in cash. On Friday, Micron’s shares closed at $362.75, gaining $26.12, or 7.76%, on roughly 47.9 million shares traded.
17 January 2026
··
1 … 706 707 708 709 710 … 1,604

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Go toTop